[PDF][PDF] Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports
Eur Rev Med Pharmacol Sci, 2021•academia.edu
OBJECTIVE: Although remdesivir (GS-5734) has recently demonstrated clinical benefits
against the pandemic outbreak of coronavirus disease 2019 (COVID-19),
neuropsychological adverse reactions (ADRs) remain to be examined in real-world settings.
Therefore, we aimed to identify and characterize the neuropsychological ADRs associated
with remdesivir use. MATERIALS AND METHODS: We obtained data for this international
pharmacovigilance cohort study from individual case safety reports
against the pandemic outbreak of coronavirus disease 2019 (COVID-19),
neuropsychological adverse reactions (ADRs) remain to be examined in real-world settings.
Therefore, we aimed to identify and characterize the neuropsychological ADRs associated
with remdesivir use. MATERIALS AND METHODS: We obtained data for this international
pharmacovigilance cohort study from individual case safety reports
Abstract
OBJECTIVE: Although remdesivir (GS-5734) has recently demonstrated clinical benefits against the pandemic outbreak of coronavirus disease 2019 (COVID-19), neuropsychological adverse reactions (ADRs) remain to be examined in real-world settings. Therefore, we aimed to identify and characterize the neuropsychological ADRs associated with remdesivir use.
MATERIALS AND METHODS: We obtained data for this international pharmacovigilance cohort study from individual case safety reports
academia.edu
以上显示的是最相近的搜索结果。 查看全部搜索结果